The PHARLAP-RCT is a prospective, multi-centre, randomised controlled trial of the clinical efficacy of a ventilation strategy (called PHARLAP) compared to standard mechanical ventilation in acute respiratory distress syndrome (ARDS) patients across Australia and New Zealand.
Goal: PHARLAP is a ventilation strategy we have designed that combines Tidal volume (Vt) and plateau pressure (Pplat) limitation with a comprehensive open lung strategy. The study will investigate the clinical efficacy of the PHARLAP strategy compared to standard mechanical ventilation in ARDS patients across Australia and New Zealand. The primary outcome is ventilator free days at day 28. In addition, physiological, inflammatory, clinical and economic outcome variables will be compared between both groups. In a prospective, multi-centre, randomised controlled trial we will enrol 340 adult patients who have developed ARDS within the past 48 hours and randomly allocate them to either the PHARLAP or a control ventilation strategy.
Rationale: ARDS is an inflammatory condition of the lung, which is associated with devastatingly high morbidity and mortality. Vt and Pplat minimisation have been shown to decrease mortality in these patients.
Study Progress: The PHARLAP-RCT is due to commence in 2012. The enrolment target is 340 patients across Australia and New Zealand.
Contact: For further information about this study, please contact the ANZIC-RC PHARLAP-RCT Project Manager, Victoria Bennett, by email.
Data Entry Webpage: https://pharlap.org.au